Indira Gandhi Memorial Hospital Pharmaceutical Import Profile — Maldives (DGFT 2022–2026)

Name: Indira Gandhi Memorial Hospital Pharmaceutical Import Records from India — 5 Products, $962.1K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Indira Gandhi Memorial Hospital — Pharmaceutical Importer Profile (2026) | 5 Products, $962.1K Trade | TransData Nexus

Indira Gandhi Memorial Hospital

Pharmaceutical Importer · Maldives · Advanced Oncology Focus · $962.1K Total Trade · DGFT Verified

Indira Gandhi Memorial Hospital is a pharmaceutical importer based in Maldives with a total trade value of $962.1K across 5 products in 1 therapeutic categories. Based on 106 verified import shipments from Indian Customs (DGFT) records, Indira Gandhi Memorial Hospital is the #1 buyer in 2 products including Osimertinib, Pembrolizumab. Indira Gandhi Memorial Hospital sources from 1 verified Indian supplier, with Nu Hospitals Private Limited accounting for 100.0% of imports.

Indira Gandhi Memorial Hospital — Import Portfolio & Supplier Network

Indira Gandhi Memorial Hospital import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Indira Gandhi Memorial Hospital?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Nu Hospitals Private Limited	$4.9M	1,633	100.0%

Indira Gandhi Memorial Hospital sources from 1 verified Indian supplier across 1,151 distinct formulations. The sourcing is highly concentrated — Nu Hospitals Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Trastuzumab - injections - 440MG -	$141.4K	15
Iron sucrose - injections - 100MG -	$112.4K	11
Sevelamar - injections - 800MG - revelabatch no	$106.9K	3
Sevelamer - tablets - 800MG - revela	$100.0K	2
Sevelamer carbonate - tablets - 800MG	$90.3K	2
Durvalumab - injections - 500MG -	$85.8K	6
Osimertinib - tablets - 80MG -	$78.6K	2
Denosumab - injections - 60MG -	$72.1K	10
Trastuzumab injections 440MG canmab batch no	$66.8K	2
Mycophenolate mofetil - tablets - 250MG	$66.4K	6
Cinacalcet - tablets - 30MG - cinnima batch no	$59.7K	2
Ceftazidime + avibactam - injections -	$54.3K	7
Bevacizumab - injections - 100MG - krabeva batch no	$52.7K	2
Erythropoietin injections 4000iu epotrend batch no	$50.0K	1
Mycophenolate mofetil - tablets - 250MG- mofilet batch no	$50.0K	1

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Trastuzumab	Advanced Oncology	$654.7K	61	0.8%	15
2	Osimertinib	Advanced Oncology	$130.8K	4	12.0%	1
3	Pembrolizumab	Advanced Oncology	$130.1K	30	6.7%	1
4	Cetuximab	Advanced Oncology	$34.5K	6	4.1%	3
5	Nivolumab	Advanced Oncology	$12.0K	5	0.5%	7

Indira Gandhi Memorial Hospital imports 5 pharmaceutical products across 1 categories into Maldives totaling $962.1K. The company is the #1 buyer for 2 products: Osimertinib, Pembrolizumab.

Indira Gandhi Memorial Hospital — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Indira Gandhi Memorial Hospital (IGMH) is the largest government-owned multi-specialty tertiary care facility in the Maldives, located in the capital city of Malé. Established on April 15, 1995, IGMH replaced the previous Central Hospital, which was later demolished to make way for another hospital. The hospital is dedicated to Indira Gandhi and serves as a significant healthcare provider in the region.

As a state-owned entity, IGMH operates under the Ministry of Health and is fully covered by the Aasandha social healthcare insurance scheme. The hospital offers a wide range of services across various departments, including Anesthesiology, Cardiology, Dentistry, Dermatology, Dietetics & Nutrition, Emergency & Trauma, Endocrinology, ENT, Gastroenterology, Gynaecological Oncology, Internal Medicine, Laboratory Medicine, Nephrology, Neurology, Neurosurgery, Obstetrics & Gynecology, Oncology, Ophthalmology, Oral and Maxillofacial Surgery, Orthopedics, Paediatrics, Paediatric Cardiology, Paediatric Neurology, Physiotherapy, Plastic & Reconstructive Surgery, Psychiatry, Pulmonology, Radiology, Rheumatology, Surgery, Surgical Oncology, Speech Therapy, and Urology. (igmh.gov.mv)

2Distribution Network

IGMH's distribution network primarily focuses on the procurement and distribution of pharmaceutical products essential for its diverse medical services. The hospital's logistics capabilities are designed to ensure the timely and efficient delivery of medical supplies to various departments, maintaining a continuous supply chain to meet patient care needs. While specific details about warehouse locations and geographic coverage are not publicly disclosed, IGMH's central location in Malé facilitates access to international shipping routes, enabling the importation of medical supplies from global suppliers.

3Industry Role

In the Maldives' pharmaceutical supply chain, IGMH functions as a primary hospital supplier, directly importing and distributing pharmaceutical products necessary for its operations. The hospital's role is critical in ensuring the availability of essential medications and medical supplies, thereby supporting the healthcare needs of the population. IGMH's direct procurement from international suppliers underscores its pivotal position in the nation's healthcare infrastructure.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Indira Gandhi Memorial Hospital

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

IGMH's pharmaceutical sourcing exhibits a high degree of concentration, with a total import value of $962,000 USD from India across 106 shipments, focusing exclusively on five oncology products. This concentrated sourcing strategy indicates a strategic choice to streamline procurement processes and maintain consistency in product quality. The exclusive reliance on a single supplier, NU Hospitals Private Limited, for all shipments suggests a stable and long-term relationship, potentially reducing procurement complexities and ensuring reliable supply. However, this single-source dependency also poses risks, such as vulnerability to supply chain disruptions or changes in supplier terms.

2Supply Chain Resilience

The resilience of IGMH's Indian supply chain appears robust, given the consistent procurement of finished pharmaceutical formulations from a single supplier, NU Hospitals Private Limited. The hospital's focus on a limited number of oncology products may enhance supply chain stability by simplifying logistics and inventory management. However, the lack of backup suppliers and limited formulation diversity could expose IGMH to risks if the primary supplier faces operational challenges or regulatory issues. Additionally, the hospital's reliance on a single shipping route for imports may increase exposure to logistical disruptions.

Importing Pharmaceuticals into Maldives — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Maldives

1Regulatory Authority & Framework

The Maldives Food and Drug Authority (MFDA) is the primary regulatory body overseeing the importation, manufacture, distribution, and sale of pharmaceuticals in the Maldives. The MFDA operates under the Ministry of Health and is responsible for ensuring that all medicinal products meet established safety, efficacy, and quality standards. The MFDA's regulations are designed to protect public health by regulating the pharmaceutical supply chain and ensuring that only approved and safe medications are available in the market. (maldivesvoice.mv)

2Import Licensing & GMP

Import licensing requirements in the Maldives stipulate that all medicine importers and sellers must be registered and licensed by the MFDA. Only drugs listed under the country's Approved Drug List are permitted for import and distribution. The MFDA recognizes Good Manufacturing Practice (GMP) certificates from reputable international standards, including EU GMP, WHO GMP, and PIC/S, ensuring that imported pharmaceuticals adhere to high-quality manufacturing standards. Additionally, wholesale distribution authorization is required for entities involved in the distribution of pharmaceutical products within the country. (maldivesvoice.mv)

Quality & Labeling

Indira Gandhi Memorial Hospital — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

IGMH's focus on importing oncology products, specifically trastuzumab, osimertinib, pembrolizumab, cetuximab, and nivolumab, aligns with the hospital's strategic emphasis on providing comprehensive cancer care services. The high demand for these medications in the Maldives, driven by the prevalence of cancer cases and the hospital's commitment to offering advanced treatment options, necessitates a reliable supply of these critical drugs. The importation of these specific therapeutic areas underscores IGMH's dedication to enhancing patient outcomes through access to cutting-edge oncology treatments.

2Sourcing Profile

IGMH's sourcing strategy is centered on procuring finished pharmaceutical formulations, particularly in the oncology therapeutic area, from India. This approach ensures access to high-quality medications that meet international standards. The hospital's exclusive reliance on a single supplier, NU Hospitals Private Limited, reflects a strategic decision to maintain consistency in product quality and streamline procurement processes. However, this strategy also highlights the importance of establishing contingency plans to mitigate potential risks associated with single-source dependency.

3Market Positioning

Seller's Guide — How to Become a Supplier to Indira Gandhi Memorial Hospital

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with IGMH, especially in the oncology therapeutic area. While the hospital currently relies on a single supplier, the high demand for specialized medications and the potential benefits of diversifying its supplier base present avenues for collaboration. Indian exporters can explore these opportunities by demonstrating compliance with MFDA regulations, ensuring product quality, and establishing reliable supply chains to meet IGMH's procurement standards.

2Requirements & Qualifications

Indian exporters seeking to supply pharmaceuticals to IGMH and the Maldives market must obtain the necessary import licenses and wholesale distribution authorizations from the Maldives Food and Drug Authority (MFDA). Products must adhere to recognized Good Manufacturing Practice (GMP) standards, such as EU GMP, WHO GMP, or PIC/S. Additionally, compliance with batch testing, stability requirements, labeling language mandates, and serialization regulations is essential to meet the MFDA's quality and safety standards.

3How to Approach

Frequently Asked Questions — Indira Gandhi Memorial Hospital

What products does Indira Gandhi Memorial Hospital import from India?

Indira Gandhi Memorial Hospital imports 5 pharmaceutical products across 1 categories. Top imports: Trastuzumab ($654.7K), Osimertinib ($130.8K), Pembrolizumab ($130.1K), Cetuximab ($34.5K), Nivolumab ($12.0K).

Who supplies pharmaceuticals to Indira Gandhi Memorial Hospital from India?

Indira Gandhi Memorial Hospital sources from 1 verified Indian suppliers. The primary supplier is Nu Hospitals Private Limited (100.0% of imports, $4.9M).

What is Indira Gandhi Memorial Hospital's total pharmaceutical import value?

Indira Gandhi Memorial Hospital's total pharmaceutical import value from India is $962.1K, based on 106 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Indira Gandhi Memorial Hospital focus on?

Indira Gandhi Memorial Hospital imports across 1 categories. The largest: Advanced Oncology (100.0%).

Get Full Indira Gandhi Memorial Hospital Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.